Endothelin(A) receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension

Circulation

Volumn 97, Issue 21, 1998, Pages 2169-2174

  Prié, Stéphane ^a   Stewart, Duncan J ^b   Dupuis, Jocelyn ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Drugs; Endothelin; Endothelium; Pulmonary heart disease

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; CALCIMYCIN; DARUSENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; MONOCROTALINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR; NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, RAT; PHENYLPROPIONIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RECEPTOR BLOCKING; SMOOTH MUSCLE CONTRACTILITY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; VASODILATION;

EID: 0032474287     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.21.2169     Document Type: Article

References (31)

1. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996;94:1578-1584.
2. B receptors. J Appl Physiol. 1996;81:1510-1515.
3. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464-469.
4. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
5. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
6. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 1993;73:887-897.
7. A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol. 1995;269:L690-L697.
8. A receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther. 1997;282:1312-1318.
9. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishila Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353-355.
10. Eddahibi S, Springall D, Mannan M, Carville C, Chabrier PE, Levame M, Raffestin B, Polak J, Adnot S. Dilator effect of endothelins in pulmonary circulation: changes associated with chronic hypoxia. Am J Physiol. 1993;265:L571-L580.
11. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation. 1995;91:771-775.
12. Okada M, Yamashita C, Okada M, Okada K. Endothelin receptor antagonists in a beagle model of pulmonary hypertension: contribution to possible potential therapy? J Am Coll Cardiol. 1995;25:1213-1217.
13. A-receptor blockade in angiotensin II-induced hypertension. Hypertension. 1997;29:435-441.
14. A-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett. 1996;2:90-92.
15. Madden JA, Keller PA, Choy JS, Alvarez, TA, Hacker AD. L-Arginine-related responses to pressure and vasoactive agents in monocrotaline-treated rat pulmonary arteries. J Appl Physiol. 1995;79:589-593.
16. Altiere RJ, Olson JW, Gillespie MM. Altered pulmonary vascular smooth muscle responsiveness in monocrotaline-induced pulmonary hypertension. J Pharmacol Exp Ther. 1986;236:390-395.
17. Wanstall JC, Hughes IE, O'Donnell SR. Reduced relaxant potency of nitroprusside on pulmonary artery preparations taken from rats during the development of hypoxic pulmonary hypertension. Br J Pharmacol. 1992;107:407-413.
18. Wanstall JC, O'Donnell SR. Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats. Br J Pharmacol. 1992;105:152-158.
19. Maruyama J, Maruyama K. Impaired nitric oxide-dependent responses and their recovery in hypertensive pulmonary arteries of rats. Am J Physiol. 1994;266:H2476-H2488.
20. Mathew R, Zeballos GA, Tun H, Gewitz MH. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats. Cardivasc Res. 1995;30:739-746.
21. Russ RD, Walker BR. Maintained endothelium-dependem pulmonary vasodilation following chronic hypoxia in the rat. J Appl Phsiol. 1993;74:339-344.
22. Isaacson TC, Hampl V, Weir EK, Nelson DP, Archer SL. Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. J Appl Physiol. 1994;76:933-940.
23. Archer SL, Rist K, Nelson DP, DeMaster EG, Cowan N, Weir EK. Comparison of the hemodynamic effects of nitric oxide and endothelium-dependent vasodilators in intact lungs. J Appl Physiol. 1990;68:735-747.
24. Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR. Selective upregulatinn of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol. 1997;272;H806-H813.
25. Ferrario L, Amin HM, Sugimori K, Camporesi EM, Hakim TS. Site of action of endogenous nitric oxide on pulmonary vasculature in rats. Pflugers Arch. 1996;432:523-527.
26. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, Large SR, Wells FC, Wallwork J. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991;324:1539-1547.
27. Dinh-Xuan AT, Higenbottam TW, Clelland C, Pepke-Zaba J, Cremona G, Wallwork J. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol. 1990;99:9-10.
28. Xue C, Johns RA. Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:1642-1644.
29. A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol. 1994;266:H1327-H1331.
30. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K, Sugishita Y. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. J Am Call Cardiol. 1996;28:1580-1588.
31. Gillespie MN, Olson JW, Reinsel CN, O'Connor WN, Altiere RJ. Vascular hyperresponsiveness in perfused lungs from monocrotalinetreated rats. Am J Physiol. 1986;251:H109-H114.